Renal Disease Market Overview
Renal Disease Market trends report has valued the industry size at USD 38.10 billion in 2022. The Renal Disease Market industry is projected to grow from USD 42.36 billion in 2023 to USD 89.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.20 % during the forecast period (2023 - 2030), reveals Market Research Future (MRFR) in a minutely analyzed research report.
The market has been growing persistently on account of rising prevalence of renal diseases across the globe which necessitates diagnosis and treatment. The rise in the geriatric population who are at more risk of kidney failures and other renal diseases boost the growth of the market. High prevalence of diabetes is also a critical factor in stimulating the growth of the market.
Diabetes remains a significant risk factor for renal diseases, especially kidney failure. Initiatives undertaken by governments of various countries to increase awareness and also various healthcare schemes launched for the prevention and treatment of renal diseases spur the growth of the market. Significant expansion of the healthcare industry, the rising prevalence of chronic kidney disease, increase in Clinical trials and R&D activities are other driving factors for the growth of the market.
However, the market growth might be restrained by high costs of treatment. Technological advancement and new product development are expected to provide opportunities for growth over the forecast period.
Segmentation
The global renal disease market has been segmented based on type, diagnosis, and treatment.
By type, the market has been segmented into acute kidney problems, chronic kidney diseases, and others. The acute kidney problems segment has been further segmented into Prerenal, Post renal, and Renal.
By diagnosis, the market has been segmented into Blood tests, Urine tests, imaging tests, removing a sample of kidney tissue for testing, and others. The blood tests segment has been further segmented into Serum Creatinine, Glomerular Filtration Rate (GFR), Blood Urea Nitrogen (BUN), and fasting blood glucose test. The urine test segment has been further segmented into Urinalysis, Protein urine test, Microalbuminuria test, Creatinine Clearance test. The imaging test segment has been further segmented into ultrasound and CT scan.
By treatment, the market has been segmented into Medications, Dialysis, Kidney transplant, Surgery, Diet and others. The medication segment has been further segmented into High blood pressure medications, Medications to lower cholesterol levels, Medications to treat anemia, Medications to relieve swelling, and Medications to protect your bones.
The dialysis segment has been further segmented into Hemodialysis, and Peritoneal dialysis. The kidney transplant segment has been further segmented into Deceased-donor kidney transplant, Living-donor kidney transplant, and Pre-emptive kidney transplant.
The surgery segment has been further segmented into Nephrectomy and radical nephrectomy, nephron-sparing surgery (NSS), nephrolithotripsy, extracorporeal shock wave lithotripsy (ESWL), and others.
Regional Analysis
The global renal disease market spans across the regions of the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas account for the largest share of the global renal disease market followed by Europe. The America market for renal disease is dominated by the US owing to high health care spending, favorable reimbursement scenario and the presence of a large patient population in the region.
Europe market is going strong on account of a robust healthcare sector and availability of funds for R&D.
Germany, France, Italy, UK, and Spain are the key contributors to the Europe market for renal diseases.
Asia Pacific is expected to grow at a relatively faster rate, led by Japan, China, India, and South Korea.
The Middle East & Africa market is expected to exhibit moderate growth over the forecast period and will be led by the Gulf economies of UAE, Saudi Arabia, and others.
Competitive Landscape
The top key players profiled in the renal disease market outlook report include Abbott (US), Baxter (US), Keryx Biopharmaceuticals, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Amgen Inc. (US), Bristol-Myers Squibb Company (US), NephroGenex, Inc. (US), Pfizer Inc.(US), Shire Pharmaceuticals Limited (Republic of Ireland), and others.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com